Repros announces results of its Androxal efficacy study for secondary hypogonadism

Editorial Checklist Reviewed
Oct 7 2009NewsGuard 100/100 Score

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary. The study was designed to compare Androxal to Testim®1% (Auxilium Pharmaceuticals Inc, Malvern, PA), an approved topical testosterone gel, indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Transdermal testosterone use has been associated with suppression of pituitary gonadotrophic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH), both necessary for stimulating testosterone production and spermatogenesis in the testes. Androxal is an oral therapy intended to restore normal brain-pituitary-testes interaction and thus testicular function in men with secondary hypogonadism.

Source:

http://www.reprosrx.com

Posted in: Men's Health News | Medical Condition News

Tags: , , , , , , , , , ,

Comments (1)

Suggested Reading

CAR T cell therapy breakthroughs bring new hope for treating solid tumors
Public trust in COVID-19 vaccine science influences vaccine uptake in the US
Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
Studies link gut dysbiosis to pancreatic cancer, offering pathways for early detection
New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk
Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Comments

  1. Explain Secondary Hypogonadism Please
    Junkman Junkman United States says:
    October 9, 2009 at 7:56 AM

    I would like to see more about what IS secondary hypogonadism, it's cause(s), if known, treatment(s) now used, if any, and consequences of the condition or disease. (In other words, tell me WHY this is important).

    I wanted to forward this, but as is, there is little reason to do so, as it contains little useful information to one not already familiar with the condition. (Or disease, if you prefer)
    Also, a bit about why, or how, this treatment works, why that is better than HRT, and expected outcomes. How is this new drug better, in other words? (Lots of us guys suffer from this, in some form or another, and sometimes as a secondary result of some other, primary disease, and/or treatment, drugs for other conditions, etc)
    Junkman

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Key reason why some cancers do not respond to immunotherapy identified